Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study
- 1 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 66 (8), 2826-2832
- https://doi.org/10.1007/s10620-020-06569-9
Abstract
Background Autoimmune hepatitis (AIH) is a chronic liver disease able to progress to acute liver failure, cirrhosis, and liver cancer. A significant proportion of patients fail to first-line therapy or develop severe toxicity. Aims To assess safety and effectiveness of tacrolimus as a second-line therapy in AIH patients. Methods Multicentric retrospective study of AIH patients treated with tacrolimus for at least 3 months as a second-line therapy. Effectiveness was defined as complete normalization of transaminases and IgG. Results A total of 23 AIH patients were included in the final analysis. In 13% of patients tacrolimus was initiated because of toxicity to previous first-line treatments and the rest were switched because of previous non-efficacy. Tacrolimus was effective in 18 patients (78%; 95%CI: 55.20-91.92%). The median time receiving tacrolimus was 16 months (IQR 20). There was a sustained response with a significant improvement in all liver enzymes and IgG on last follow-up. Only one patient discontinued tacrolimus at the third month because of severe neuropathy, and ototoxicity. Responders were significantly older at diagnosis of AIH (41 +/- 13vs.27 +/- 10 years old;p = 0.0496). Conclusion Tacrolimus is effective and well tolerated as a second-line therapy in patients with AIH.This publication has 19 references indexed in Scilit:
- The clinical phenotypes of autoimmune hepatitis: A comprehensive reviewJournal of Autoimmunity, 2015
- Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapyScandinavian Journal of Gastroenterology, 2015
- EASL Clinical Practice Guidelines: Autoimmune hepatitisJournal of Hepatology, 2015
- Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experienceAlimentary Pharmacology & Therapeutics, 2011
- Simplified criteria for the diagnosis of autoimmune hepatitisHepatology, 2008
- Incidence of HAV and HBV Infections and Vaccination Rates in Patients With Autoimmune Liver DiseasesThe American Journal of Gastroenterology, 2008
- Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitisWorld Journal of Gastroenterology, 2007
- Transplant immunosuppressive agents in non‐transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimusLiver International, 2005
- Efficacy of Tacrolimus in the Treatment of Steroid Refractory Autoimmune HepatitisJournal of Clinical Gastroenterology, 2004
- Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic HepatitisQJM: An International Journal of Medicine, 1971